USD
+$0.00
(+0.00%
)At Close (As of Nov 5, 2025)
$2.11M
Market Cap
0.0351
P/E Ratio
29.9
EPS
$16.63
52 Week High
$1.03
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | -$16K |
| Total Revenue | $0 |
| Cost Of Revenue | $16K |
| Costof Goods And Services Sold | $16K |
| Operating Income | -$15M |
| Selling General And Administrative | $3M |
| Research And Development | $12M |
| Operating Expenses | $15M |
| Investment Income Net | - |
| Net Interest Income | $87K |
| Interest Income | $101K |
| Interest Expense | $14K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $16K |
| Income Before Tax | -$15M |
| Income Tax Expense | $8K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$15M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$15M |
| Ebitda | -$15M |
| Net Income | -$15M |
| Field | Value (USD) |
|---|---|
| Total Assets | $4.5M |
| Total Current Assets | $4.4M |
| Cash And Cash Equivalents At Carrying Value | $4.3M |
| Cash And Short Term Investments | $4.3M |
| Inventory | - |
| Current Net Receivables | $119K |
| Total Non Current Assets | $97K |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $48K |
| Other Non Current Assets | - |
| Total Liabilities | $2.7M |
| Total Current Liabilities | $2.4M |
| Current Accounts Payable | $296K |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $90K |
| Total Non Current Liabilities | $259K |
| Capital Lease Obligations | $45K |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $45K |
| Other Current Liabilities | $2.1M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $1.8M |
| Treasury Stock | - |
| Retained Earnings | -$56M |
| Common Stock | - |
| Common Stock Shares Outstanding | $454K |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$13M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $16K |
| Capital Expenditures | $13K |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | -$13K |
| Cashflow From Financing | $8.9M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$15M |
| Field | Value (USD) |
|---|---|
| Gross Profit | -$16K |
| Total Revenue | $0 |
| Cost Of Revenue | $16K |
| Costof Goods And Services Sold | $16K |
| Operating Income | -$15M |
| Selling General And Administrative | $3M |
| Research And Development | $12M |
| Operating Expenses | $15M |
| Investment Income Net | - |
| Net Interest Income | $87K |
| Interest Income | $101K |
| Interest Expense | $14K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $16K |
| Income Before Tax | -$15M |
| Income Tax Expense | $8K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$15M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$15M |
| Ebitda | -$15M |
| Net Income | -$15M |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC
PainReform Ltd. is a pioneering pharmaceutical company headquartered in Tel Aviv, Israel, specializing in the development of advanced therapies aimed at extending post-surgical pain relief. Through its proprietary drug delivery technology, the company addresses critical pain management challenges, enhancing the effectiveness and safety of analgesics. With a strong focus on transforming patient care in the postoperative environment, PainReform is well-positioned to lead innovations in the evolving pain management landscape, catering to both healthcare providers and patients in need of effective pain solutions.